CLINICAL TRIALS PROFILE FOR CORGARD
✉ Email this page to a colleague
All Clinical Trials for CORGARD
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00670267 ↗ | Oral Nadolol for the Treatment of Adults With Mild Asthma | Completed | Baylor College of Medicine | Phase 1/Phase 2 | 2007-01-01 | The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness. |
| NCT00670267 ↗ | Oral Nadolol for the Treatment of Adults With Mild Asthma | Completed | Sandler Program for Asthma Research | Phase 1/Phase 2 | 2007-01-01 | The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness. |
| NCT00670267 ↗ | Oral Nadolol for the Treatment of Adults With Mild Asthma | Completed | University of Houston | Phase 1/Phase 2 | 2007-01-01 | The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness. |
| NCT00670267 ↗ | Oral Nadolol for the Treatment of Adults With Mild Asthma | Completed | Invion, Inc. | Phase 1/Phase 2 | 2007-01-01 | The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness. |
| NCT02021474 ↗ | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis | Unknown status | AgoneX Biopharmaceuticals, Inc. | Phase 2 | 2015-09-01 | This is a prospective multi-center, randomized, double-blind, two treatment period, placebo-controlled study in subjects with migraine headache requiring prophylactic treatment. The patients will be randomized to receive either histamine dihydrochloride sc or placebo (matching vehicle only) sc for 16 weeks. The safety and efficacy outcome measures will be assessed at selected dosing segments during the 16 week treatment phase and 4 weeks (week 20), 8 weeks (week 24) after the last Injection. |
| NCT02021474 ↗ | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis | Unknown status | BioHealthonomics Inc. | Phase 2 | 2015-09-01 | This is a prospective multi-center, randomized, double-blind, two treatment period, placebo-controlled study in subjects with migraine headache requiring prophylactic treatment. The patients will be randomized to receive either histamine dihydrochloride sc or placebo (matching vehicle only) sc for 16 weeks. The safety and efficacy outcome measures will be assessed at selected dosing segments during the 16 week treatment phase and 4 weeks (week 20), 8 weeks (week 24) after the last Injection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CORGARD
Condition Name
Clinical Trial Locations for CORGARD
Trials by Country
Clinical Trial Progress for CORGARD
Clinical Trial Phase
Clinical Trial Sponsors for CORGARD
Sponsor Name
